Peptides Similar to ARA-290
Compare ARA-290 with related peptides and alternatives
📌TL;DR
- •3 similar peptides identified
- •BPC-157: Both exhibit tissue-protective and repair-promoting properties
- •Semax: Both have neuroprotective properties
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| ARA-290 (current) | - | - |
| BPC-157 | Both exhibit tissue-protective and repair-promoting properties | BPC-157 is a gastric peptide with broad tissue healing effects; ARA-290 is EPO-derived and specifically targets the innate repair receptor for neuroprotection |
| Semax | Both have neuroprotective properties | Semax is an ACTH analog approved in Russia for cognitive enhancement; ARA-290 targets the innate repair receptor for nerve fiber regeneration |
| Erythropoietin (EPO) | ARA-290 is derived from EPO's tissue-protective domain | EPO activates both erythropoietic and tissue-protective pathways; ARA-290 selectively activates only the tissue-protective innate repair receptor |
BPC-157Both exhibit tissue-protective and repair-promoting properties
Differences
BPC-157 is a gastric peptide with broad tissue healing effects; ARA-290 is EPO-derived and specifically targets the innate repair receptor for neuroprotection
Advantages
BPC-157 has broader preclinical tissue healing evidence
Disadvantages
BPC-157 has limited human clinical trial data compared to ARA-290
SemaxBoth have neuroprotective properties
Differences
Semax is an ACTH analog approved in Russia for cognitive enhancement; ARA-290 targets the innate repair receptor for nerve fiber regeneration
Advantages
Semax has regulatory approval in Russia and extensive clinical use
Disadvantages
Different mechanism and target conditions
Erythropoietin (EPO)ARA-290 is derived from EPO's tissue-protective domain
Differences
EPO activates both erythropoietic and tissue-protective pathways; ARA-290 selectively activates only the tissue-protective innate repair receptor
Advantages
EPO has extensive clinical data and multiple approved indications
Disadvantages
EPO carries cardiovascular risks from erythropoiesis that ARA-290 avoids
Peptides Related to ARA-290#
ARA-290 (cibinetide) occupies a unique niche in neuroprotective peptide therapeutics as the only compound specifically designed to selectively activate the innate repair receptor. This section compares ARA-290 with other peptides that share neuroprotective or tissue-protective properties.
Erythropoietin (EPO)#
The most direct comparison for ARA-290 is with its parent molecule, erythropoietin (EPO). ARA-290 was rationally designed from EPO's structure to isolate its tissue-protective signaling from its erythropoietic effects.
EPO has been extensively studied for neuroprotective applications, including traumatic brain injury, stroke, and neuropathy. Multiple clinical trials have demonstrated EPO's tissue-protective effects. However, the simultaneous stimulation of red blood cell production creates cardiovascular risks (hypertension, thrombosis) that limit its therapeutic use for non-anemia indications.
ARA-290 eliminates this limitation by selectively activating the IRR without engaging the classical EPO receptor. This selectivity has been confirmed in clinical trials showing no changes in hematocrit or hemoglobin with ARA-290 treatment. The tradeoff is a much shorter half-life (2 minutes vs. 6-9 hours for EPO), requiring more frequent dosing.
BPC-157#
BPC-157 is a synthetic pentadecapeptide derived from human gastric juice that exhibits broad tissue-healing properties. While both ARA-290 and BPC-157 promote tissue repair, their mechanisms are fundamentally different.
BPC-157 works through multiple pathways including VEGF-VEGFR2 signaling, NO system modulation, and FAK-paxillin activation for cell migration. Its effects span gastrointestinal healing, tendon repair, and neuroprotection. ARA-290 works specifically through the innate repair receptor to modulate inflammation and promote nerve fiber regeneration.
BPC-157 has a broader evidence base in preclinical models across multiple tissue types, while ARA-290 has stronger clinical evidence in human patients, particularly for neuropathy. BPC-157 remains entirely in preclinical development, whereas ARA-290 has completed multiple Phase 2 clinical trials with measurable outcomes.
Semax#
Semax is a synthetic analog of ACTH(4-10) that has been approved in Russia for various neurological conditions including stroke recovery and cognitive enhancement. Like ARA-290, Semax has neuroprotective properties, but the mechanisms and clinical applications differ substantially.
Semax works through BDNF and NGF upregulation, modulation of neurotransmitter systems, and anti-inflammatory effects. ARA-290 works specifically through IRR activation. Semax is primarily used for cognitive enhancement and stroke recovery, while ARA-290 targets peripheral neuropathy and small fiber neuropathy.
Semax has the advantage of regulatory approval (in Russia) and decades of clinical use. ARA-290 has the advantage of a well-defined molecular target (IRR) and objective biomarker evidence (corneal nerve fiber density) in controlled clinical trials conducted to Western regulatory standards.
Summary Comparison#
| Feature | ARA-290 | EPO | BPC-157 | Semax |
|---|---|---|---|---|
| Target | IRR (EPOR-betacR) | EPOR + IRR | Multiple pathways | ACTH receptors |
| Neuroprotection | Strong (clinical data) | Strong (clinical data) | Preclinical only | Clinical data (Russia) |
| Erythropoiesis risk | None | Significant | None | None |
| Clinical trials (Western) | Phase 2 complete | Extensive | None | Limited |
| FDA status | Orphan Drug (sarcoidosis) | Approved (anemia) | Not approved | Not approved (US) |
| Key indication | Small fiber neuropathy | Anemia | Tissue healing | Cognitive/stroke |
| Half-life | ~2 minutes | 6-9 hours | >4 hours (est.) | ~30 minutes |
Clinical Positioning#
ARA-290's unique positioning lies in its selective IRR activation for neuroprotective applications without erythropoietic risk. For patients with small fiber neuropathy, particularly in sarcoidosis, there are currently no approved treatments, making ARA-290's FDA Orphan Drug designation clinically significant. The objective biomarker evidence (corneal nerve fiber density improvement) provides a measurable endpoint that differentiates it from purely symptom-based treatments.
Related Reading#
Frequently Asked Questions About ARA-290
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer